Sophia Genetics SA expected to post a loss of 23 cents a share - Earnings Preview
Sophia Genetics SA
SOPH, SOPH is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2025The Rolle Vaud-based company is expected to report a 10.6% increase in revenue to $17.48 million from $15.81 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sophia Genetics SA is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sophia Genetics SA is $7.00, about 55.3% above its last closing price of $3.13
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.26 | -0.25 | -0.26 | Missed | -5.1 |
Dec. 31 2025 | -0.25 | -0.22 | -0.23 | Missed | -2.7 |
Sep. 30 2024 | -0.24 | -0.23 | -0.28 | Missed | -21.7 |
Jun. 30 2024 | -0.28 | -0.28 | -0.23 | Beat | 18.6 |
Mar. 31 2024 | -0.27 | -0.27 | -0.21 | Beat | 23.2 |
Dec. 31 2023 | -0.25 | -0.27 | -0.37 | Missed | -37 |
Sep. 30 2023 | -0.33 | -0.32 | -0.21 | Beat | 35.1 |
Jun. 30 2023 | -0.30 | -0.31 | -0.33 | Missed | -7.7 |
This summary was machine generated August 1 at 13:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
